SHARE
Pharmaceutical Contract Development And Manufacturing Organization Cdmo Market

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Global Market Outlook (2019-2027)

5.0 (94 reviews)
Published: September 2020 ID: SMRC19952
5.0 (94 reviews)
Published: September 2020 ID: SMRC19952

This report covers the impact of COVID-19 on this global market

According to Stratistics MRC, the Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is accounted for $148.50 billion in 2019 and is expected to reach $298.07 billion by 2027 growing at a CAGR of 9.1% during the forecast period. Some of the key factors propelling the market growth include growing demand for generic medicines and biologics, growing need for state-of-the-art processes and production technologies, advent of contract development & manufacturing organization (CDMO) model, and growing investment in R&D. However, stringent government regulations are likely to hamper the market.
 

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Global Market Outlook (2019-2027)


The contract development and manufacturing organization (CDMO) industry had begun decades ago as a niche business by offering specialty services and manufacturing capacities to pharmaceutical companies. CDMOs also play a critical role in offering additional capacities and mitigate the risk of supply shortages by providing additional manufacturing and development sites and backup facilities. Issues regarding documentation and quality of drug manufacturing process during regulatory reviews can lead to delay in marketing authorization. Therefore for pharmaceutical companies, a prompt quality standard with proven reliability is a definitive key for outsourcing to CDMOs.

By service type, pharmaceutical manufacturing services segment is projected to grow at the lucrative rate during the forecast period, due to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity.

On the basis of geography, Asia-Pacific is expected to witness the significant market growth during the forecast period, owing to the low cost offered by the region, as compared to the United States and other developed economies. Additionally, growing incidences of chronic and lifestyle diseases, such as diabetes and heart disease, coupled with ease of patient recruitment and availability of expertise for clinical trials, are few driving factors boosting growth in the region. With the increasing privatization of clinical trials, there has been an increase in the outsourcing of research processes in developing regions like China and India.

Some of the key players in Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market include Famar SA, Boehringer Ingelheim Group, Catalent Inc., Pfizer CentreSource, CMIC Holdings Co. Ltd, Aenova Holding GmbH, Baxter Biopharma Solutions, Syneos Health Inc., Lonza Group , Patheon Inc., Novotech Pty Ltd, Covance Inc., Recipharm AB , SGS SA (SGS Life Sciences), Jubilant Life Sciences Ltd, Samsung Bioepis Co. Ltd, IQVIA Holdings Inc., Quanticate Ltd, PAREXEL International Corporation, and WuXi AppTec Inc.

Research Phases Covered:
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Service Types Covered:
• Pharmaceutical Manufacturing Services
• Biologics Manufacturing Services
• Drug Development Services

End Users Covered:
• Small & Mid-size Pharma
• Big Pharma
• Generic Pharmaceutical Companies

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain
o Rest of Europe      
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary       
        
2 Preface      
 
 2.1 Abstract      
 2.2 Stake Holders      
 2.3 Research Scope      
 2.4 Research Methodology      
  2.4.1 Data Mining     
  2.4.2 Data Analysis     
  2.4.3 Data Validation     
  2.4.4 Research Approach     
 2.5 Research Sources      
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions     
        
3 Market Trend Analysis       
 3.1 Introduction      
 3.2 Drivers      
 3.3 Restraints      
 3.4 Opportunities      
 3.5 Threats      
 3.6 End User Analysis      
 3.7 Emerging Markets      
 3.8 Impact of Covid-19      
        
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry      
        
5 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Research Phase       
 5.1 Introduction      
 5.2 Pre-clinical      
 5.3 Phase I       
 5.4 Phase II      
 5.5 Phase III      
 5.6 Phase IV      
        
6 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Service Type       
 6.1 Introduction      
 6.2 Pharmaceutical Manufacturing Services      
  6.2.1 Secondary Packaging     
  6.2.2 Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing     
   6.2.2.1 Liquid Dose Formulation    
   6.2.2.2 Parenteral/Injectable Dose Formulation    
   6.2.2.3 Solid Dose Formulation    
   6.2.2.4 Tablet Manufacturing Services    
   6.2.2.5 Capsule Manufacturing Services    
  6.2.3 Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing     
 6.3 Biologics Manufacturing Services      
  6.3.1 Biologics API Manufacturing     
  6.3.2 Biologics FDF Manufacturing     
 6.4 Drug Development Services      
        
7 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By End User       
 7.1 Introduction      
 7.2 Small & Mid-size Pharma      
 7.3 Big Pharma      
 7.4 Generic Pharmaceutical Companies      
        
8 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, By Geography       
 8.1 Introduction      
 8.2 North America      
  8.2.1 US     
  8.2.2 Canada     
  8.2.3 Mexico     
 8.3 Europe      
  8.3.1 Germany     
  8.3.2 UK     
  8.3.3 Italy     
  8.3.4 France     
  8.3.5 Spain     
  8.3.6 Rest of Europe     
 8.4 Asia Pacific      
  8.4.1 Japan     
  8.4.2 China     
  8.4.3 India     
  8.4.4 Australia     
  8.4.5 New Zealand     
  8.4.6 South Korea     
  8.4.7 Rest of Asia Pacific     
 8.5 South America      
  8.5.1 Argentina     
  8.5.2 Brazil     
  8.5.3 Chile     
  8.5.4 Rest of South America     
 8.6 Middle East & Africa      
  8.6.1 Saudi Arabia     
  8.6.2 UAE     
  8.6.3 Qatar     
  8.6.4 South Africa     
  8.6.5 Rest of Middle East & Africa     
        
9 Key Developments       
 9.1 Agreements, Partnerships, Collaborations and Joint Ventures      
 9.2 Acquisitions & Mergers      
 9.3 New Product Launch      
 9.4 Expansions      
 9.5 Other Key Strategies      
        
10 Company Profiling       
 10.1 Famar SA      
 10.2 Boehringer Ingelheim Group      
 10.3 Catalent Inc.      
 10.4 Pfizer CentreSource      
 10.5 CMIC Holdings Co. Ltd      
 10.6 Aenova Holding GmbH      
 10.7 Baxter Biopharma Solutions      
 10.8 Syneos Health Inc.      
 10.9 Lonza Group      
 10.10 Patheon Inc.      
 10.11 Novotech Pty Ltd      
 10.12 Covance Inc.      
 10.13 Recipharm AB      
 10.14 SGS SA (SGS Life Sciences)      
 10.15 Jubilant Life Sciences Ltd      
 10.16 Samsung Bioepis Co. Ltd      
 10.17 IQVIA Holdings Inc.      
 10.18 Quanticate Ltd      
 10.19 PAREXEL International Corporation      
 10.20 WuXi AppTec Inc.      


List of Tables        
1 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Region (2018-2027) ($MN)       
2 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)       
3 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)       
4 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)       
5 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)       
6 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)       
7 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)       
8 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)       
9 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)       
10 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)       
11 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)       
12 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)       
13 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)       
14 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)       
15 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)       
16 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)       
17 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)       
18 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)       
19 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)       
20 Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)       
21 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)       
22 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)       
23 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)       
24 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)       
25 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)       
26 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)       
27 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)       
28 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)       
29 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)       
30 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)       
31 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)       
32 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)       
33 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)       
34 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)       
35 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)       
36 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)       
37 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)       
38 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)       
39 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)       
40 North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)       
41 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)       
42 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)       
43 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)       
44 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)       
45 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)       
46 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)       
47 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)       
48 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)       
49 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)       
50 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)       
51 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)       
52 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)       
53 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)       
54 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)       
55 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)        
56 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)       
57 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)       
58 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)       
59 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)       
60 Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)       
61 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)       
62 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)       
63 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)       
64 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)       
65 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)       
66 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)       
67 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)       
68 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)       
69 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)       
70 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)       
71 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)       
72 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)       
73 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)       
74 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)       
75 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)       
76 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)       
77 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)       
78 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)       
79 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)       
80 Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)       
81 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)       
82 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)       
83 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)       
84 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)       
85 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)       
86 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)       
87 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)       
88 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)       
89 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)       
90 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)       
91 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)       
92 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)       
93 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)       
94 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)       
95 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)       
96 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)       
97 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)        
98 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)       
99 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)       
100 South America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)       
101 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Country (2018-2027) ($MN)       
102 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Research Phase (2018-2027) ($MN)       
103 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase I (2018-2027) ($MN)       
104 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase II (2018-2027) ($MN)       
105 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase III (2018-2027) ($MN)       
106 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Phase IV (2018-2027) ($MN)       
107 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pre-clinical (2018-2027) ($MN)       
108 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Service Type (2018-2027) ($MN)       
109 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Manufacturing Services (2018-2027) ($MN)       
110 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Secondary Packaging (2018-2027) ($MN)       
111 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Finished Dosage Formulation (FDF) Development and Manufacturing (2018-2027) ($MN)       
112 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Active Pharmaceutical Ingredient (API) Manufacturing (2018-2027) ($MN)       
113 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics Manufacturing Services (2018-2027) ($MN)       
114 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics API Manufacturing (2018-2027) ($MN)       
115 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Biologics FDF Manufacturing (2018-2027) ($MN)       
116 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Drug Development Services (2018-2027) ($MN)       
117 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By End User (2018-2027) ($MN)       
118 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Small & Mid-size Pharma (2018-2027) ($MN)       
119 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Big Pharma (2018-2027) ($MN)       
120 Middle East & Africa Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, By Generic Pharmaceutical Companies (2018-2027) ($MN)        

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials